192944-51-7

Basic information

• Product Name: ETHYL 1H-INDAZOLE-5-CARBOXYLATE
• Synonyms: 1H-INDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER;ETHYL 1H-INDAZOLE-5-CARBOXYLATE;1H-Indazole-5-carboxylicacid,ethylester(9CI);5-(Ethoxycarbonyl)-1H-indazole;Ethyl Indazole-5-carboxylate;ETHYL 1H-INDAZOLE-5-CARBOXYLAT
• CAS NO: 192944-51-7
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Product Categories: CARBOXYLICESTER;pharmacetical
• Mol File: 192944-51-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 122-124℃
• Boiling Point: 353.9°Cat760mmHg
• Flash Point: 167.8°C
• Appearance: /
• Density: 1.272g/cm³
• Vapor Pressure: 3.47E-05mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 12.81±0.40(Predicted)
• CAS DataBase Reference: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(192944-51-7)
• EPA Substance Registry System: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(192944-51-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 192944-51-7(Hazardous Substances Data)

Usage

General Description

ETHYL 1H-INDAZOLE-5-CARBOXYLATE is a chemical compound with the molecular formula C11H10N2O2. It belongs to the class of organic compounds known as indazoles and is derived from the carboxylation of 1H-indazole-5-amine. It is commonly used in organic synthesis and pharmaceutical research due to its potential biological activities, including anti-inflammatory and anti-cancer properties. ETHYL 1H-INDAZOLE-5-CARBOXYLATE is a solid, usually white in color, and is soluble in organic solvents like ethanol, methanol, and dichloromethane. It is important to handle this chemical with care as it may pose hazards if mishandled or improperly used.

InChI:InChI=1/C10H10N2O2/c1-2-14-10(13)7-3-4-9-8(5-7)6-11-12-9/h3-6H,2H2,1H3,(H,11,12)

Upstream product

• 64-17-5 ethanol 
• 61700-61-6 1H-indazole-5-carboxylic acid 
• 40800-65-5 1-amino-2-methylbenzene-4-carboxylic acid ethyl ester 
• 2486-70-6 4-amino 3-methylbenzoic acid 
• 108-24-7 acetic anhydride 
• 192944-50-6 ethyl 1-acetyl-1H-indazole-5-carboxylatee 

Downstream Products

• 1005205-25-3 1H-indazole-5-carbohydrazide 
• 1314398-37-2 ethyl 1-methyl-1H-indazole-5-carboxylate 
• 1334405-45-6 ethyl 2-methyl-2H-indazole-5-carboxylate 
• 1092961-11-9 (1-methyl-1H-indazol-5-yl)methanol 
• 1252781-30-8 1-(3-trifluoromethyl-phenyl)-1H-indazole-5-carboxylic acid 
• 1252781-31-9 2-(3-trifluoromethyl-phenyl)-2H-indazole-5-carboxylic acid 
• 1252780-11-2 ethyl 1-(3-trifluoromethyl-phenyl)-1H-indazole-5-carboxylate 
• 1252780-12-3 ethyl 2-(3-trifluoromethyl-phenyl)-2H-indazole-5-carboxylate 

Relevant articles and documents

Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors

Abstract Glycolysis is drastically increased in tumors and it is the main route to energy production with a minor use of oxidative phosphorylation. Among the key enzymes in the glycolytic process, LDH is emerging as one of the most interesting targets for the development of new inhibitors. In this context, in the present work, we carried out a virtual screening procedure followed by chemical modifications of the identified structures according to a "hit-to-lead" process. The effects of the new molecules were preliminary probed against purified human LDH-A. The compounds active at low micromolar level were additionally characterized for their activity on some cellular metabolic processes by using Raji human cell line. Within the series, 1 was considered the best candidate, and a more detailed characterization of its biological properties was performed. In Raji cells exposed to compound 1 we evidenced the occurrence of effects usually observed in cancer cells after LDH-A inhibition: reduced lactate production and NAD/NADH ratio, apoptosis. The flow cytometry analysis of treated cells also showed cell cycle changes compatible with effects exerted at the glycolytic level. Finally, in agreement with the data obtained with other inhibitors or by silencing LDH-A expression, compound 1 was found to increase Raji cells response to some commonly used chemotherapeutic agents. Taken together, all these finding are in support of the LDH-A inhibiting activity of compound 1.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.